Novo Nordisk (NYSE:NVO) is navigating a pivotal moment as Medicare's upcoming price negotiations threaten to cut into the company's biggest revenue stream. Its Ozempic and Wegovy drugs have been driving over 60% of Novo's sales. But here's the kicker: GLP-1 drugs aren't just about weight loss and diabetes anymore. A Nature Medicine study released Monday revealed that these treatments reduce Alzheimer's risk by 12%, adding to an already staggering list of benefits, including cardiovascular, kidney, and even sleep apnea treatments. Analysts suggest this new data could push governments and insurers to expand coverage for GLP-1 drugs, unlocking a much larger market.

• Warning! GuruFocus has detected 1 Warning Sign with NVO.

Competition is tightening, with Eli Lilly (NYSE:LLY) racing alongside Novo in the GLP-1 space. Novo's pipeline powerhouse, CagriSema, recently fell short of its weight-loss goals, but its established drugs continue to dominate. Analysts argue that as Novo and Lilly expand the use cases for GLP-1s, their competitive moats will grow even deeper. Meanwhile, Novo's aggressive DKK 19.4 billion share repurchase program signals confidence in weathering potential Medicare cuts. With a reputation for innovative breakthroughs and a fortified market position, Novo isn't backing down from the challenges ahead.

The future of GLP-1 drugs is looking bigger than anyone predicted. As governments consider broader adoption and competitors scramble to keep up, Novo Nordisk is well-positioned to lead this pharmaceutical revolution. Medicare price negotiations may tighten margins in the short term, but for long-term investors, the GLP-1 story is just getting started.